1. Pink Sheet
  2. >>Legal & IP

IPR-Enhancing EU-Mercosur Trade Talks Set To Resume After Stalling

 
• By Francesca Bruce

The European Commission expects talks will resume in a matter of weeks for an EU-Mercosur trade deal, which would increase intellectual property rights protection for originator medicines in the Latin American markets.

Handshake of businessmen
Could An EU-Mercosur Trade Deal Soon Be Concluded?

Trade talks between the EU and the South American trade bloc, Mercosur, look set to resume soon despite setbacks at the end of 2017, according to the European Commission. The deal, which is seeking to increase intellectual property right protection for pharmaceuticals in Mercosur markets, has come under fire from public health advocates for aiming to legitimize in Mercosur countries IPR mechanisms that are under scrutiny in Europe.

Mercosur (Argentina, Brazil, Paraguay and Uruguay) and the EU have been in talks over a free trade deal since 2000

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

Viatris Agrees To $335m Opioid Settlement Ending US State, Local Government Cases

 
• By Dean Rudge

Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic.

Pharma Predicts Modest Tariff Impact, Depending On What Comes Next

 
• By Jessica Merrill

Drugmakers are not expecting a big financial hit from tariffs for now, but a report commissioned by the industry trade association PhRMA suggests a potentially steep cost for pharma-sector tariffs.

What The EMA Can Teach HTA Bodies About Joint Clinical Assessments

 
• By Francesca Bruce

EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.